Federal Register #2026-18951

NIH Licensing Opportunity: Monoclonal Antibody for RSV G Protein

The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is offering a technology licensing opportunity for a novel monoclonal antibody targeting the RSV G protein. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) - Technology Transfer and Intellectual Property Office - OEMs and Vendors: - NIH (as the technology originator and licensor) - Products/Technologies Offered: - Monoclonal antibody targeting a conserved region of the RSV attachment protein G - Part Number: E11720240 - IgG3 and IgG1 subclasses - High neutralizing potency - Potential for first-in-class RSV prevention or treatment - Available for licensing and collaborative research - Unique/Notable Requirements: - Opportunity is for technology licensing and collaboration, not product procurement - Focus on RSV (Respiratory Syncytial Virus) therapeutic development - Technology is positioned for commercial development and further research - No specific quantities or recurring services are requested - No resellers or third-party vendors are involved; NIH is the sole licensor

Description

This notice announces an amendment to a previously scheduled meeting of the Center for Scientific Review under the National Institutes of Health. The amendment changes the meeting times and duration for specific study sections, including the Applied Immunology and Disease Control Integrated Review Group and the Center for Scientific Review Special Emphasis Panel. The meetings are virtual and closed to the public, focusing on reviewing and evaluating grant applications. The notice provides contact information and details about the meeting format and agenda.

View original listing